

Goat anti-human PAI-2 IgG

Product No. ADG74

Description

Plasminogen Activator Inhibitor Type 2 (PAI-2) is one of two endogenous inhibitors of urokinase-type plasminogen activator (urokinase, uPA). PAI-2 is a member of the serpin family of protease inhibitors. It exists as a 48 kDa non-glycosylated form found in placental tissue and a 60 kDa glycosylated secreted form found in maternal blood and ascitic fluid.

Generally PAI-2 is undetectable in the majority of peripheral blood samples. However levels of PAI-2 appear to be higher in patient's ascitic fluid from malignant tumors, as compared to benign tumors (1). PAI-2 levels appear to increase during pregnancy, reaching 120-550 ng/mL in the third trimester (2, 3).

Preparation

From goats immunized with recombinant human PAI-2. The IgG fraction of immunoserum was isolated by affinity chromatography on Protein G-Sepharose.

Presentation

Screw-capped clear glass vial containing 1.0 mg of purified IgG lyophilized from 1 mL PBS with 200 mM mannitol, pH 7.5.

Reconstitution

Add 1 mL of filtered deionized water. Agitate gently for 5 minutes.

Storage and Stability

Store unopened vials at 2 - 8 °C until the expiration date shown on label.

Store reconstituted antibody in aliquots at -20 °C or colder. Stable for at least 6 months; avoid repeated freeze and thaw cycles.

Applications

ELISA

The antibody can be used as capture or detection antibody in ELISAs.(3)

Western Blot

The antibody can be used for immuno-blotting (4).

Immunohistochemistry

The antibody can be used for immunohistological staining of frozen (5,6) and formalin-fixed, paraffin-embedded tissue sections (7).

References

1. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Casslén B et al., Eur J Cancer. 1994;30A(9):1302-1309.
2. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. Lecander I et al., Br J Haematol. 1984 Jul;57(3):407-412.
3. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy. Estellés A et al., Thromb Haemost. 1990 Oct 22;64(2):281-285.
4. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator. Reinartz J et al., Exp Cell Res. 1996 Feb 25;223(1):91-101.
5. Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis. Schaefer BM, et al., Autoimmunity. 1996;23(3):155-164.
6. alpha 2-Antiplasmin and plasminogen activator inhibitors in healing human skin wounds. Schaefer BM et al., Arch Dermatol Res. 1996 Mar;288(3):122-128
7. Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques. Ferrier CM et al., J Histochem Cytochem. 1998 Apr;46(4):469-476.

Distributed by:

LOXO GMBH

IMMUNOLOGIE • MOLEKULARBIOLOGIE
BIOCHEMIE • PRODUKTE UND SYSTEME

Gerhart-Hauptmann-Str. 48
69221 Dossenheim

Tel +49 6221 868023
Fax +49 6221 8680255

www.loxo.de - info@loxo.de

Hinweis/Note:

Der Packungsbeileger dient nur als erste Information. Der relevante Packungsbeileger liegt der Ware bei.

The datasheet is for information purposes only. The current datasheet will be enclosed with product shipment.

For research use only!

ADG74©08072019